Source comparison
Claim by Claim: Animal Evidence vs Human Evidence
Every claim on a typical AOD 9604 sales page traces back to one of these rows. Stimulates lipolysis Yes, obese Zucker rats and ob/ob mice (Ng 2000; Heffernan 2001) Not measured as fat mass in any positive confirmatory trial Animal only Inhibits lipogenesis Yes
This comparison does not assign a generated winner or score.
- Every claim on a typical AOD 9604 sales page traces back to one of these rows.
- Stimulates lipolysis
- Yes, obese Zucker rats and ob/ob mice (Ng 2000; Heffernan 2001)
- Not measured as fat mass in any positive confirmatory trial
- Animal only
- Inhibits lipogenesis
- Yes, isolated adipose tissue (Ng 2000)
- Never tested
- Requires the beta-3 adrenergic receptor
- Yes, beta-3 AR knockout mice were unresponsive (Heffernan, Endocrinology, 2001)
- Produces weight loss
- Over 50% reduction in body weight gain, oral 500 mcg/kg, 19 days
- 2.6 kg vs 0.8 kg placebo at 12 weeks; nothing significant at 24 weeks in 536 adults
- Failed to replicate
- Does not raise IGF-1
- Not applicable
- Confirmed across six RCTs (Stier 2013)
- Supported
- Does not impair glucose tolerance
- Euglycemic clamp in rats showed no insulin resistance (Ng 2000)
- No carbohydrate metabolism abnormality across six RCTs
- Not immunogenic
- No anti-AOD9604 antibodies detected (Stier 2013)
- Supported for oral and IV
- Repairs cartilage
- Rabbit collagenase osteoarthritis model, 0.25 mg intra-articular weekly, better with hyaluronic acid (Kwon & Park, Ann Clin Lab Sci, 2015)
- None
- Works by subcutaneous injection
- Not the tested route
- Zero controlled trials
- Untested
- Safe beyond six months
- No human trial ran past 24 weeks
- Unknown
- The pattern is consistent. Everything AOD 9604 is sold for rests on rodent and rabbit data. Everything AOD 9604 has proven in humans is a negative: it does not raise IGF-1, it does not wreck glucose tolerance, it does not provoke antibodies. Those are real findings. None of them is fat loss.